NCT04940286 2026-04-16
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
564 trialsNCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT05065801 2026-04-15
GABRINOX2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT07126158 2026-04-15
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Recruiting
NCT05632328 2026-04-08
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT04820179 2026-04-02
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
Phase 2 Active not recruiting
NCT07504471 2026-03-31
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
Ruijin Hospital
Phase 2 Recruiting
NCT05068752 2026-03-30
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Completed
NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT03601923 2026-03-25
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04331041 2026-03-25
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT06538623 2026-03-24
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
Phase 2 Completed
NCT06756074 2026-03-16
Reinforced Pancreaticojejunostomy With or Without glubran2
Minia University
Phase 2 Recruiting
NCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT04975516 2026-03-03
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Terminated
NCT04485286 2026-02-27
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Massachusetts General Hospital
Phase 2 Recruiting
NCT05014776 2026-02-24
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
NCT06906562 2026-02-17
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07415525 2026-02-17
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
Zhejiang University
Phase 2 Not yet recruiting
NCT03983057 2026-02-11
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
Phase 2 Completed
NCT04115163 2026-02-11
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05908747 2026-02-10
Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT06015659 2026-02-09
ZN-c3 + Gemcitabine in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06662006 2026-02-06
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT03727880 2026-02-04
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT06411795 2026-02-03
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
NCT03264404 2026-01-27
Azacitidine and Pembrolizumab in Pancreatic Cancer
Columbia University
Phase 2 Completed
NCT06951997 2026-01-26
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT07354919 2026-01-21
AxeCan
HealthPartners Institute
Phase 2 Not yet recruiting
NCT05026905 2026-01-20
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT06168812 2026-01-15
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07344220 2026-01-15
DZ-002-201
Hoag Memorial Hospital Presbyterian
Phase 2 Enrolling by invitation
NCT03977233 2026-01-13
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT03104439 2026-01-12
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03322995 2026-01-08
PANC
Medical College of Wisconsin
Phase 2 Recruiting
NCT04241276 2026-01-07
STARPAC2
Queen Mary University of London
Phase 2 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06547736 2026-01-05
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Fudan University
Phase 2 Recruiting
NCT07131514 2026-01-02
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Ruijin Hospital
Phase 2 Recruiting
NCT03443492 2025-12-30
Pancreas
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT03991962 2025-12-24
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Active not recruiting
NCT03745794 2025-12-23
Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
M.D. Anderson Cancer Center
Phase 2 Completed